» Articles » PMID: 28174233

Circular RNA CiRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2017 Feb 9
PMID 28174233
Citations 265
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer is one of the most common malignancies worldwide. Recently, a novel circular RNA, ciRS-7, was proposed to be a potential miR-7 sponge. As miR-7, a putative tumor-suppressor, regulates the expression of several important drivers of colorectal cancer, we analyzed the clinical significance of ciRS-7 in colorectal cancer patients. Initially, we evaluated the expression levels of ciRS-7 in a training cohort comprising of 153 primary colorectal cancer tissues and 44 matched normal mucosae. We subsequently confirmed its clinical relevance in an independent validation cohort ( = 165), and evaluated the effect of ciRS-7 on miR-7, and its target genes EGFR and RAF1. Functional analyses were performed in cell lines and an animal model to support clinical findings. Our data revealed that ciRS-7 was significantly upregulated in colorectal cancer tissues compared with matched normal mucosae ( = 0.0018), and its overexpression was associated with poor patient survival ( = 0.0224 and 0.0061 in the training and validation cohorts, respectively). Multivariate survival analysis revealed that ciRS-7 emerged as an independent risk factor for overall survival ( = 0.0656 and 0.0324 in the training and validation cohorts, respectively). Overexpression of ciRS-7 in HCT116 and HT29 cells led to the blocking of miR-7 and resulted in a more aggressive oncogenic phenotype, and ciRS-7 overexpression permitted the inhibition of miR-7 and subsequent activation of EGFR and RAF1 oncogenes. CiRS-7 is a promising prognostic biomarker in colorectal cancer patients and may serve as a therapeutic target for reducing EGFR-RAF1 activity in colorectal cancer patients. .

Citing Articles

The prognosis of ciRS-7 and circHIPK3 in pan-cancer: a mini-review and meta-analysis.

Li X, Wu T, Dong R, Wu X Discov Oncol. 2025; 16(1):207.

PMID: 39969753 PMC: 11839969. DOI: 10.1007/s12672-025-01944-2.


Adeno-associated virus mediated artificial circular RNA for triggering cancer immunotherapy to treat prostate cancer.

Ye C, Liu Z, Xie Q, Tang Y, Zeng J, Feng Z Front Oncol. 2025; 15:1443571.

PMID: 39959665 PMC: 11827427. DOI: 10.3389/fonc.2025.1443571.


Circular RNAs in cancer: roles, mechanisms, and therapeutic potential across colorectal, gastric, liver, and lung carcinomas.

Malviya A, Bhuyan R Discov Oncol. 2025; 16(1):5.

PMID: 39755870 PMC: 11700081. DOI: 10.1007/s12672-025-01743-9.


Circular RNA CDR1as/ciRS-7- a novel biomarker in solid tumors.

Zhang Y, Xiong C, Jiang Z, Wang X, Ji J, Pan Y Front Oncol. 2024; 14:1468363.

PMID: 39678511 PMC: 11638042. DOI: 10.3389/fonc.2024.1468363.


The crosstalk between alternative splicing and circular RNA in cancer: pathogenic insights and therapeutic implications.

Hu H, Tang J, Wang H, Guo X, Tu C, Li Z Cell Mol Biol Lett. 2024; 29(1):142.

PMID: 39550559 PMC: 11568689. DOI: 10.1186/s11658-024-00662-x.


References
1.
Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

2.
Hur K, Toiyama Y, Schetter A, Okugawa Y, Harris C, Boland C . Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J Natl Cancer Inst. 2015; 107(3). PMC: 4334826. DOI: 10.1093/jnci/dju492. View

3.
Hur K, Toiyama Y, Okugawa Y, Ide S, Imaoka H, Boland C . Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer. Gut. 2015; 66(4):654-665. PMC: 4919275. DOI: 10.1136/gutjnl-2014-308737. View

4.
Li J, Zheng Y, Sun G, Xiong S . Restoration of miR-7 expression suppresses the growth of Lewis lung cancer cells by modulating epidermal growth factor receptor signaling. Oncol Rep. 2014; 32(6):2511-6. DOI: 10.3892/or.2014.3519. View

5.
Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S . MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2014; 36(3):338-45. DOI: 10.1093/carcin/bgu242. View